PE20071364A1 - Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb - Google Patents

Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb

Info

Publication number
PE20071364A1
PE20071364A1 PE2007000122A PE2007000122A PE20071364A1 PE 20071364 A1 PE20071364 A1 PE 20071364A1 PE 2007000122 A PE2007000122 A PE 2007000122A PE 2007000122 A PE2007000122 A PE 2007000122A PE 20071364 A1 PE20071364 A1 PE 20071364A1
Authority
PE
Peru
Prior art keywords
procedure
weight loss
administering
eating disorders
unwanted weight
Prior art date
Application number
PE2007000122A
Other languages
English (en)
Inventor
Lin John Chia-Yang
Arnon Rosenthal
Jennifer Renee Stratton
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of PE20071364A1 publication Critical patent/PE20071364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO QUE CONSISTE EN LA ADMINISTRACION DE NEUROTROFINA-4/5 (NT-4/5) POR VIA PERIFERICA EL CUAL ES UN ANTICUERPO ANTI-AGONISTA DE TrkB. DICHA NEUROTROFINA ES AGONISTA DE TIROSINA QUINASA B (TrkB) UTILES EN EL TRATAMIENTO DE CAQUEXIA, ANOREXIA NERVIOSA, PERDIDA DE PESO NO DESEADA, O EMESIS INDUCIDA POR OPIOIDES
PE2007000122A 2006-02-02 2007-02-02 Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb PE20071364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76541006P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
PE20071364A1 true PE20071364A1 (es) 2008-01-30

Family

ID=38093467

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000122A PE20071364A1 (es) 2006-02-02 2007-02-02 Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb

Country Status (17)

Country Link
US (2) US20070248611A1 (es)
EP (1) EP1988923A1 (es)
JP (1) JP2009528985A (es)
KR (1) KR20080091838A (es)
CN (1) CN101400367A (es)
AR (1) AR059304A1 (es)
AU (1) AU2007210862A1 (es)
BR (1) BRPI0707482A2 (es)
CA (1) CA2637826A1 (es)
DO (1) DOP2007000021A (es)
IL (1) IL193069A0 (es)
NL (1) NL2000464C2 (es)
PE (1) PE20071364A1 (es)
RU (1) RU2008131939A (es)
TW (1) TW200808352A (es)
UY (1) UY30128A1 (es)
WO (1) WO2007088476A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5
KR20090088896A (ko) * 2006-11-09 2009-08-20 아이알엠 엘엘씨 효현제 ｔｒｋｂ 항체 및 그의 용도
JP2010513461A (ja) * 2006-12-20 2010-04-30 ライナット ニューロサイエンス コーポレイション 自己免疫障害を治療するためのＴｒｋＢアゴニスト
CA2703329A1 (en) * 2007-10-23 2009-04-30 Novartis Ag Use of trkb antibodies for the treatment of respiratory disorders
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
WO2017085035A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
DK0550665T3 (da) * 1990-09-25 1996-12-02 Genentech Inc Ny neurotrofisk faktor
US6506728B2 (en) * 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
DK0487301T3 (da) * 1990-11-20 2000-09-18 Dade Behring Marburg Gmbh Fremgangsmåde til stabilisering af enzymkonjugater
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2143739A1 (en) * 1992-09-07 1994-03-17 Andrew T. Holder Growth hormone potentiating molecules
WO1994006455A1 (en) * 1992-09-14 1994-03-31 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
US5759573A (en) * 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP2534968B2 (ja) * 1993-05-27 1996-09-18 チッソ株式会社 フラビン還元酵素遺伝子
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU2589095A (en) * 1994-05-16 1995-12-05 Washington University Cell membrane fusion composition and method
AU689920B2 (en) * 1994-06-24 1998-04-09 Dade Behring Marburg Gmbh Method of stabilizing molecules, or parts of molecules, which are sensitive to hydrolysis
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
ES2293662T3 (es) 1996-11-15 2008-03-16 Genentech, Inc. Purificacion de neurotrofinas.
CN1250379A (zh) * 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
IL134536A0 (en) * 1997-08-29 2001-04-30 Vertex Pharma Compounds possessing neuronal activity and pharmaceutical compositions containing the same
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
PT1409654E (pt) * 1999-06-16 2008-11-25 Boston Biomedical Res Inst Controlo imunológico dos níveis de beta-amilóide in vivo
JP2004510684A (ja) * 1999-07-06 2004-04-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド 神経学的疾患の治療のためのアゾアミノ酸誘導体
JP2003503476A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミド誘導体
JP2003503484A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド アミノアルキル誘導体
WO2001002405A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
JP2003503482A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミノ酸誘導体
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
DK1223966T3 (da) * 1999-10-29 2003-08-18 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDNF til behandling af hornhindedefekter
WO2001060398A1 (fr) * 2000-02-18 2001-08-23 Sumitomo Pharmaceuticals Company, Limited Medicaments destines a ameliorer l'intolerance au glucose
EP1262189A1 (en) * 2000-03-06 2002-12-04 Sumitomo Pharmaceuticals Company, Limited Leptin-resistance ameliorating agents
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
CN1529599A (zh) * 2001-06-14 2004-09-15 ��̩��˹ҩ��ɷ����޹�˾ 可用于治疗神经元损伤的无环哌嗪和哌啶衍生物
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5

Also Published As

Publication number Publication date
JP2009528985A (ja) 2009-08-13
IL193069A0 (en) 2009-02-11
KR20080091838A (ko) 2008-10-14
AR059304A1 (es) 2008-03-26
US20090291897A1 (en) 2009-11-26
US20070248611A1 (en) 2007-10-25
WO2007088476A1 (en) 2007-08-09
CN101400367A (zh) 2009-04-01
TW200808352A (en) 2008-02-16
AU2007210862A1 (en) 2007-08-09
NL2000464C2 (nl) 2007-09-11
CA2637826A1 (en) 2007-08-09
EP1988923A1 (en) 2008-11-12
NL2000464A1 (nl) 2007-08-03
BRPI0707482A2 (pt) 2011-05-03
RU2008131939A (ru) 2010-02-10
DOP2007000021A (es) 2007-08-31
UY30128A1 (es) 2007-09-28

Similar Documents

Publication Publication Date Title
PE20071364A1 (es) Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb
FR21C1031I2 (fr) Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
GT200600046A (es) Terapia de combinacion
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CR9291A (es) Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f, y sus usos
ECSP066722A (es)
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
BRPI0820271A2 (pt) Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
AR057239A1 (es) Inmunoglobulinas
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
UY27793A1 (es) Pirazolopiridinas substituidas con carbamato
ECSP067091A (es) Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CO6180432A2 (es) Anticuerpos agonistas del trkb y usos de los mismos
ECSP066336A (es) Derivados de 3-amino croman y 2-amino tetralin
BRPI0517647A (pt) combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina
GT200600135A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
CY1110046T1 (el) Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων
ECSP088315A (es) Moduladores de hexahidro-ciclooctil pirazol cannabinoide
CR10336A (es) Compuestos organicos y sus usos
DOP2010000062A (es) Derivados de ciclopropilamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal